Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
159
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

236
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
236
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

181
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
181
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

227
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
227
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

477
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
477
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

174
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
174

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pancreatic Cystic Lesions and Endoscopic Ultrasound Diagnostic Equipment: A Literature Review.

Journal of clinical medicine·2026
Same author

Correlation Between Psoas and Diaphragmatic Ultrasound Indices for the Assessment of Sarcopenia in Patients with Inflammatory Bowel Disease: A Prospective Single-Center Study.

Nutrients·2026
Same author

Dieulafoy lesion of the gastrointestinal tract: what's new? A narrative review.

European journal of gastroenterology & hepatology·2026
Same author

Comparison Between Transient Elastography and Point Shear Wave Elastography in the Assessment of Liver Fibrosis According to the Grade of Liver Steatosis.

Journal of clinical medicine·2025
Same author

Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events.

Biomolecules·2025
Same author

Basal Cell Carcinoma: An Old Friend with Multiple Faces.

Cancers·2025

相关实验视频

Updated: Jul 29, 2025

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
06:31

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Published on: June 2, 2023

1.0K

检查点抑制剂诱导的结肠炎:一个更新

Giuseppe Losurdo1, Daniele Angelillo1, Nicolas Favia1

  • 1Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", 70124 Bari, Italy.

Biomedicines
|May 27, 2023
PubMed
概括

免疫检查点抑制剂 (ICI) 可能导致结肠炎,这是影响患者的常见副作用. 管理范围从轻度病例的支持性护理到严重ICI相关大肠炎的皮质类固醇和生物药物.

关键词:
癌症 癌症 癌症 癌症 癌症大肠炎是一种大肠炎.腹 腹 腹 腹 腹 腹免疫检查点抑制剂 免疫检查点抑制剂免疫疗法 免疫疗法

更多相关视频

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.9K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

977

相关实验视频

Last Updated: Jul 29, 2025

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
06:31

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Published on: June 2, 2023

1.0K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.9K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

977

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 胃肠病学 胃肠病学

背景情况:

  • 针对CTLA-4,PD-1和PD-L1的免疫检查点抑制剂 (ICI) 用于固体瘤.
  • 通过ICI过度刺激免疫系统可能会导致不良影响,特别是ICI相关的大肠炎.
  • 与ICI相关的结肠炎表现出腹和腹痛等症状,显著影响患者的生活质量.

研究的目的:

  • 审查ICI相关大肠炎的临床表现,分级,组织学特征和管理策略.
  • 为免疫检查点抑制剂诱导肠球炎提供当前治疗方法的概述.

主要方法:

  • 关于ICI相关大肠炎的文献综述.
  • 对临床表现,诊断标准和组织学发现的分析.
  • 根据严重程度进行治疗干预的总结.

主要成果:

  • 与ICI相关的结肠炎是癌症免疫治疗的常见和致残的副作用.
  • 使用常用术语标准对不良事件 (CTCAE) 评级系统来评估严重程度.
  • 组织学发现是非特异性的,但可以分为五种类型.
  • 治疗包括支持性护理,抗腹药物,皮质类固醇,以及潜在的生物药物,如因弗利西马布或维多利祖马布,用于耐火病例.

结论:

  • 与ICI相关的大肠炎的有效管理对于患者的福祉和治疗的延续至关重要.
  • 从支持性护理到先进疗法,需要逐步的方法来管理ICI诱导的肠球炎.
  • 进一步的研究可能会完善这种免疫疗法并发症的诊断和治疗策略.